Articles and Insights About Wearables for Clinical Trials

VivoSense Awarded NIA/MassAITC Grant to Aid in Alzheimer's Research

Posted by Dudley Tabakin on January 19, 2023

VivoSense, a trusted leader in the development, validation, and delivery of digital clinical measures, announced today that it has been awarded a research grant funded by the National Institute of Aging (NIA) and the Massachusetts Artificial Intelligence and Technology Center for Connected Care in Aging & Alzheimer’s Disease (MassAITC; grant number 5P30AG073107-02 Pilot A2).

Read More

The Next-Generation 6MWT: Best 6-Minute Effort (B6ME™)

Posted by Kate Lyden on January 13, 2023

Movement and mobility-related information collected passively and continuously from digital health technologies (DHTs) as patients go about their daily lives can significantly advance our understanding of patient functioning. The Best 6-Minute Effort (B6ME)™ is a novel outcome measure that captures the maximum effort exerted by a patient as they go about their typical daily life, providing insight into their lived experience.

Here's an overview of what B6ME™ is and how it augments the 6MWT to provide additional granularity of patient functioning and novel movement and mobility-related outcomes.

Read More

Opportunities for Real-World Measures in Alzheimer's Research

Posted by Jen Blankenship on November 23, 2022

Alzheimer’s disease (AD) is a devastating neurodegenerative disease that progresses to impact every dimension of a patient’s life. With no cure and limited options to manage symptoms, research is underway to develop drugs that impact the most burdensome aspects of AD: memory problems and the ability to function independently.

Read More

Measuring Physical Function and Mobility in Real World Settings

Posted by Jen Blankenship on November 4, 2022

Physical function and mobility are relevant to virtually all clinical indications and are significant determinants of an individual’s quality of life. Because of this, function and mobility are often assessed in clinical trials using subjective questionnaires or in-clinic performance tests, but these assessments may not reflect a patient’s lived experience. Wearable sensors provide an opportunity to move assessments of function into the real world to measure how patients feel and function in their everyday environments.

Read More

VivoSense Joins DiMe Physical Activity Project

Posted by Kate Lyden on October 31, 2022

We are excited to announce our participation in DiMe's Physical Activity, the latest digital clinical measures project. In partnership with the Digital Medicine Society (DiMe) and other leaders in the field, we are developing a core set of digital measures for tracking patients’ physical activity across any therapeutic area.

Clinicians, researchers, and drug developers need to have a shared baseline of digital measures to improve our patients’ health, regardless of their disease or condition. By taking an omni-therapeutic approach, we believe we can reduce time and risk, speeding the development of new therapies to market. Read more about the project.

Read More

Wearable Sensors and Validating Outcome Measures in Clinical Trials

Posted by Dudley Tabakin on September 22, 2022

In this Hitlab panel discussion, VivoSense CEO Dudley Tabakin and Industry Principal Paul Sonnier discuss validating digital endpoints for their delivery in clinical trials using a patient-first approach that substantiates the efficacy or performance of their treatment.

Read More

Digital Health Expert, Ieuan Clay, Joins VivoSense Science Team

Posted by Rob Wilson on June 16, 2022

Vivosense is pleased to announce that Ieuan Clay has joined the company as Director of Science. He brings extensive knowledge in developing and validating novel digital measures gained across experiences in industry, healthtech and academia.

Read More

VivoSense Joins DTRA to Accelerate Adoption of Decentralized Trials

Posted by Rob Wilson on June 9, 2022

VivoSense, an agile end-to-end digital clinical endpoint solutions company developing digital endpoints from wearable sensors with their proprietary AI-enabled software platform is proud to join an alliance of over one hundred and twenty life sciences and healthcare organizations that seek to accelerate the broad adoption of patient-focused, decentralized clinical trials and research. The Decentralized Trials & Research Alliance (DTRA), is uniting industry stakeholders, including healthcare companies, regulators, patient groups, research organizations and technology providers with a singular mission to make clinical trial participation widely accessible by advancing policies, research practices and new technologies in decentralized clinical research.

Read More

Stijn Rogiers Interview About Accelerating Digital Endpoints

Posted by Stijn Rogiers on May 26, 2022

SAS Principal Industry Consultant Stijn Rogiers interviewed VivoSense CEO Dudley Tabakin about the uptake in decentralized clinical trials in response to the ongoing disruptions caused by the Coronavirus pandemic of 2020. As trials move toward decentralization, new processes and strategies are required to effectively collect and analyze patient data in a meaningful and validated way. Here are a few key takeaways from their conversation.

Read More

Pharmaphorum Interview: Accelerating Wearables in Clinical Trials

Posted by pharmaphorum on May 11, 2022

Pharmaphorum interviewed VivoSense CEO Dudley Tabakin and new board members from Xontogeny and Debiopharm to discuss how VivoSense’s recent $25M Series A Financing round will help scale up VivoSense® software and accelerate the use of wearable sensors data in clinical trials.

Read More

Subscribe to Email Updates

Stay Connected

Popular